Copyright: ©Author(s) 2026.
World J Clin Oncol. Aug 24, 2026; 17(8): 123328
Published online Aug 24, 2026. doi: 10.5306/wjco.123328
Published online Aug 24, 2026. doi: 10.5306/wjco.123328
Table 2 Frequency of genomic alterations detected across the targeted next-generation sequencing panel, n (%)
| Gene | Total cohort mutated (n = 48) | ccRCC subgroup mutated (n = 39) | TCGA benchmark[1] |
| VHL | 17 (35.4) | 15 (38.5) | Approximately 50% |
| PBRM1 | 12 (25.0) | 10 (25.6) | Approximately 30% |
| SETD2 | 7 (14.6) | 6 (15.4) | Approximately 12% |
| ATM | 6 (12.5) | - | Approximately 3% |
| TP53 | 6 (12.5) | - | Approximately 3%-4% |
| KDM5C | 4 (8.3) | - | Approximately 6% |
| TSC1 | 4 (8.3) | - | Rare |
| MTOR | 3 (6.3) | - | Approximately 7% |
| TSC2 | 3 (6.3) | - | Rare |
| PIK3CA | 2 (4.2) | - | Rare |
| BAP1 | 2 (4.2) | - | Approximately 10% |
| MET | 0 (0.0) | 0 (0.0) | Rare (ccRCC)/approximately 13% (pRCC) |
- Citation: Talwar V, Jain A, Goel V, Agarwal B, Gupta P, Tripathi R, Rawal S, Mehta A. Genomic landscape and clinical actionability of renal cell carcinoma in an Indian cohort: A real-world targeted next-generation sequencing study. World J Clin Oncol 2026; 17(8): 123328
- URL: https://www.wjgnet.com/2218-4333/full/v17/i8/123328.htm
- DOI: https://dx.doi.org/10.5306/wjco.123328